660 related articles for article (PubMed ID: 21059503)
1. Botulinum toxin type A and acute drug costs in migraine with triptan overuse.
Christie SN; Giammarco R; Gawel M; Mackie G; Gladstone J; Becker WJ
Can J Neurol Sci; 2010 Sep; 37(5):588-94. PubMed ID: 21059503
[TBL] [Abstract][Full Text] [Related]
2. Humanistic, utilization, and cost outcomes associated with the use of botulinum toxin for treatment of refractory migraine headaches in a managed care organization.
Mitchell MP; Schaecher K; Cannon HE; Speckman M
J Manag Care Pharm; 2008 Jun; 14(5):442-50. PubMed ID: 18597573
[TBL] [Abstract][Full Text] [Related]
3. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
Cady R; Schreiber C
Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
[TBL] [Abstract][Full Text] [Related]
4. [Botulinum toxin type A (Relatox) in transition from medication overuse to non-overuse status in patients with chronic migraine: a subgroup analysis of phase IIIb randomized single-blind multicenter active-controlled parallel-group trial].
Artemenko AR; Abramov VG; Bozhenkina TV; Konovalova ZN; Korenko AN; Krasavina DA; Kurenkov AL; Latysheva NV; Naprienko MV; Orlova OR; Filatova EG; Shevchenko VS; Iakovleva PN
Zh Nevrol Psikhiatr Im S S Korsakova; 2023; 123(11):64-74. PubMed ID: 37994890
[TBL] [Abstract][Full Text] [Related]
5. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.
Silberstein SD; Blumenfeld AM; Cady RK; Turner IM; Lipton RB; Diener HC; Aurora SK; Sirimanne M; DeGryse RE; Turkel CC; Dodick DW
J Neurol Sci; 2013 Aug; 331(1-2):48-56. PubMed ID: 23790235
[TBL] [Abstract][Full Text] [Related]
6. Adding Additional Acute Medications to a Triptan Regimen for Migraine and Observed Changes in Headache-Related Disability: Results From the American Migraine Prevalence and Prevention (AMPP) Study.
Buse DC; Serrano D; Reed ML; Kori SH; Cunanan CM; Adams AM; Lipton RB
Headache; 2015 Jun; 55(6):825-39. PubMed ID: 25881857
[TBL] [Abstract][Full Text] [Related]
7. Botulinum toxin type A for migraine prophylaxis in the Japanese population: an open-label prospective trial.
Suzuki K; Iizuka T; Sakai F
Intern Med; 2007; 46(13):959-63. PubMed ID: 17603233
[TBL] [Abstract][Full Text] [Related]
8. Duration of migraine is a predictor for response to botulinum toxin type A.
Eross EJ; Gladstone JP; Lewis S; Rogers R; Dodick DW
Headache; 2005 Apr; 45(4):308-14. PubMed ID: 15836566
[TBL] [Abstract][Full Text] [Related]
9. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
Winner PK; Sadowsky CH; Martinez WC; Zuniga JA; Poulette A
Headache; 2012 Sep; 52(8):1219-25. PubMed ID: 22607530
[TBL] [Abstract][Full Text] [Related]
10. Impact of NSAID and Triptan use on developing chronic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study.
Lipton RB; Serrano D; Nicholson RA; Buse DC; Runken MC; Reed ML
Headache; 2013; 53(10):1548-63. PubMed ID: 23992516
[TBL] [Abstract][Full Text] [Related]
11. Identifying the factors underlying discontinuation of triptans.
Wells RE; Markowitz SY; Baron EP; Hentz JG; Kalidas K; Mathew PG; Halker R; Dodick DW; Schwedt TJ
Headache; 2014 Feb; 54(2):278-89. PubMed ID: 24001117
[TBL] [Abstract][Full Text] [Related]
12. Botulinum toxin type A as an effective prophylactic treatment in primary headache disorders.
Blumenfeld A
Headache; 2003 Sep; 43(8):853-60. PubMed ID: 12940806
[TBL] [Abstract][Full Text] [Related]
13. [Botulinum toxin A in chronic refractory migraine: premarketing experience].
Álvaro-González LC; Fernández-García JM; Aranzábal-Alustiza I; Castillo-Calvo B; Iriondo-Etxenagusia I; Rodríguez-Antigüedad A
Rev Neurol; 2012 Oct; 55(7):385-91. PubMed ID: 23011856
[TBL] [Abstract][Full Text] [Related]
14. Botulinum Toxin Type A in the treatment of chronic migraine without medication overuse.
Freitag FG; Diamond S; Diamond M; Urban G
Headache; 2008 Feb; 48(2):201-9. PubMed ID: 18042229
[TBL] [Abstract][Full Text] [Related]
15. Refractory chronic migraine: is drug withdrawal necessary before starting a therapy with onabotulinum toxin type A?
Butera C; Colombo B; Bianchi F; Cursi M; Messina R; Amadio S; Guerriero R; Comi G; Del Carro U
Neurol Sci; 2016 Oct; 37(10):1701-6. PubMed ID: 27395386
[TBL] [Abstract][Full Text] [Related]
16. Factors associated with triptan use in episodic migraine: results from the American Migraine Prevalence and Prevention Study.
Chu MK; Buse DC; Bigal ME; Serrano D; Lipton RB
Headache; 2012 Feb; 52(2):213-23. PubMed ID: 22413150
[TBL] [Abstract][Full Text] [Related]
17. Monocentric Prospective Study into the Sustained Effect of Incobotulinumtoxin A (XEOMIN
Ion I; Renard D; Le Floch A; De Verdal M; Bouly S; Wacongne A; Lozza A; Castelnovo G
Toxins (Basel); 2018 Jun; 10(6):. PubMed ID: 29857565
[TBL] [Abstract][Full Text] [Related]
18. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group.
Silberstein S; Mathew N; Saper J; Jenkins S
Headache; 2000 Jun; 40(6):445-50. PubMed ID: 10849039
[TBL] [Abstract][Full Text] [Related]
19. [Botulinum toxin type A (Relatox) in the treatment of chronic migraine in adults: results of phase IIIb, randomized, one-blind, multicenter, active-controlled, parallel-group trial].
Artemenko AR; Abramov VG; Konovalova ZN; Korenko AN; Krasavina DA; Kurenkov AL; Latysheva NV; Naprienko MV; Orlova OR; Filatova EG; Shevchenko VS; Yakovleva PN
Zh Nevrol Psikhiatr Im S S Korsakova; 2023; 123(5):89-99. PubMed ID: 37315247
[TBL] [Abstract][Full Text] [Related]
20. Triptans use and overuse: A pharmacoepidemiology study from the French health insurance system database covering 4.1 million people.
Braunstein D; Donnet A; Pradel V; Sciortino V; Allaria-Lapierre V; Lantéri-Minet M; Micallef J
Cephalalgia; 2015 Nov; 35(13):1172-80. PubMed ID: 25667299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
